1h Free Analyst Time
About Systemic Psoriasis Therapeutics
Speak directly to the analyst to clarify any post sales queries you may have.
Psoriasis is a chronic skin disease affecting about 2% of the world’s population. Different forms of psoriasis include plaque, inverse, pustular, and guttate psoriasis.
The analysts forecast the Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 10.07% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the systemic psoriasis therapeutics market. To calculate the market size, the report considers the revenue generated from sale of different systemic psoriasis therapeutics.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
The report, systemic psoriasis therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- AbbVie
- Amgen
- Celgene
- Johnson & Johnson
Market drivers
- Need for affordable therapies
- For a full, detailed list, view the full report
Market challenges
- Patent expiry of drugs
- For a full, detailed list, view the full report
Market trends
- Rise in cost of systemic psoriasis therapy
- For a full, detailed list, view the full report
Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 03: RESEARCH METHODOLOGYPART 12: CUSTOMER LANDSCAPEPART 14: DECISION FRAMEWORK
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE ANALYSIS
PART 08: MARKET SEGMENTATION BY PRODUCT
PART 09: MARKET SEGMENTATION BY ROA
PART 10: MARKET SEGMENTATION BY SEVERITY OF DISEASE
PART 11: MARKET SEGMENTATION BY END-USER
PART 13: REGIONAL LANDSCAPE
PART 15: DRIVERS AND CHALLENGES
PART 16: MARKET TRENDS
PART 17: VENDOR LANDSCAPE
PART 18: VENDOR ANALYSIS
PART 19: APPENDIX
List of Exhibits
Executive Summary
New Report Released: - Global Systemic Psoriasis Therapeutics Market 2018-2022The author of the report recognizes the following companies as the key players in the global systemic psoriasis therapeutics market: AbbVie, Amgen, Celgene, and Johnson & Johnson.
Commenting on the report, an analyst from the research team said: “One trend affecting this market is the rise in cost of systemic psoriasis therapy. The cost of the treatment depends on the severity of the disease. The first line of treatment is usually a systemic agent, and if ineffective a more potent systemic agent is used which increases the cost of treatment.”
According to the report, one driver influencing this market is the need for affordable therapies. Topical treatments are most often purchased medication. Biologics are the most expensive medication and treatment failure can increase the medication cost.
Further, the report states that one challenge affecting this market is the patent expiry of drugs. The patent for major biologics for systemic psoriasis therapy have expired, which increases chances of adoption of biosimilars.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie
- Amgen
- Celgene
- Johnson & Johnson